Research record
KIT-altered melanoma
KIT alterations may matter more in some melanoma subtypes, including acral and mucosal melanoma, and can justify asking about KIT-directed evidence or trials.
What this is
KIT alterations may matter more in some melanoma subtypes, including acral and mucosal melanoma, and can justify asking about KIT-directed evidence or trials.
Why it may come up
- NCI PDQ notes trial evidence for patients with cannot be removed by surgery stage III or stage IV melanoma and a KIT pathogenic variant.
- The exact KIT mutation matters; not every KIT alteration predicts the same therapy discussion.
What not to assume
- Do not generalize from one KIT drug or case report to all KIT-altered melanoma.
- Ask whether the alteration is activating/actionable.
- Gene
- KIT
- Cancer type
- melanoma
- Last checked
- 2026-05-20
What we know
- NCI PDQ notes trial evidence for patients with cannot be removed by surgery stage III or stage IV melanoma and a KIT pathogenic variant.
- The exact KIT mutation matters; not every KIT alteration predicts the same therapy discussion.
What is unclear
- Do not generalize from one KIT drug or case report to all KIT-altered melanoma.
- Ask whether the alteration is activating/actionable.
Questions to ask
- Which parts of this result are actionable?
- Which parts are mainly useful for trial search?
- Would a melanoma specialty center review change the conversation?